The proper identification of candidates for dual HER2-targeted therapy without chemotherapy remains a challenge and disease biomarkers may elucidate the subset of HER2+ breast cancers that are primarily dependent on HER2 signaling for growth and that may respond to HER2 directed therapies without chemotherapy. Here, ERBB2 is linked to breast cancer.